1
|
Feola S, Haapala M, Peltonen K, Capasso C, Martins B, Antignani G, Federico A, Pietiäinen V, Chiaro J, Feodoroff M, Russo S, Rannikko A, Fusciello M, Koskela S, Partanen J, Hamdan F, Tähkä SM, Ylösmäki E, Greco D, Grönholm M, Kekarainen T, Eshaghi M, Gurvich OL, Ylä-Herttuala S, M. Branca RM, Lehtiö J, Sikanen TM, Cerullo V. PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification. ACS NANO 2021; 15:15992-16010. [PMID: 34605646 PMCID: PMC8552492 DOI: 10.1021/acsnano.1c04371] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 09/23/2021] [Indexed: 06/13/2023]
Abstract
Identification of HLA class I ligands from the tumor surface (ligandome or immunopeptidome) is essential for designing T-cell mediated cancer therapeutic approaches. However, the sensitivity of the process for isolating MHC-I restricted tumor-specific peptides has been the major limiting factor for reliable tumor antigen characterization, making clear the need for technical improvement. Here, we describe our work from the fabrication and development of a microfluidic-based chip (PeptiCHIP) and its use to identify and characterize tumor-specific ligands on clinically relevant human samples. Specifically, we assessed the potential of immobilizing a pan-HLA antibody on solid surfaces via well-characterized streptavidin-biotin chemistry, overcoming the limitations of the cross-linking chemistry used to prepare the affinity matrix with the desired antibodies in the immunopeptidomics workflow. Furthermore, to address the restrictions related to the handling and the limited availability of tumor samples, we further developed the concept toward the implementation of a microfluidic through-flow system. Thus, the biotinylated pan-HLA antibody was immobilized on streptavidin-functionalized surfaces, and immune-affinity purification (IP) was carried out on customized microfluidic pillar arrays made of thiol-ene polymer. Compared to the standard methods reported in the field, our methodology reduces the amount of antibody and the time required for peptide isolation. In this work, we carefully examined the specificity and robustness of our customized technology for immunopeptidomics workflows. We tested this platform by immunopurifying HLA-I complexes from 1 × 106 cells both in a widely studied B-cell line and in patients-derived ex vivo cell cultures, instead of 5 × 108 cells as required in the current technology. After the final elution in mild acid, HLA-I-presented peptides were identified by tandem mass spectrometry and further investigated by in vitro methods. These results highlight the potential to exploit microfluidics-based strategies in immunopeptidomics platforms and in personalized immunopeptidome analysis from cells isolated from individual tumor biopsies to design tailored cancer therapeutic vaccines. Moreover, the possibility to integrate multiple identical units on a single chip further improves the throughput and multiplexing of these assays with a view to clinical needs.
Collapse
Affiliation(s)
- Sara Feola
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Markus Haapala
- Drug
Research Program, Division of Pharmaceutical Chemistry and Technology,
Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
| | - Karita Peltonen
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Cristian Capasso
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Beatriz Martins
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Gabriella Antignani
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Antonio Federico
- Faculty
of
Medicine and Health Technology, Tampere
University, Arvo Ylpön
katu 34, Tampere 33520, Finland
| | - Vilja Pietiäinen
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
- Institute
for Molecular Medicine Finland, FIMM, Helsinki Institute of Life Science
(HiLIFE), University of Helsinki, Biomedicum 2U, Tukholmankatu 8, 00290 Helsinki, Finland
| | - Jacopo Chiaro
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Michaela Feodoroff
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
- Institute
for Molecular Medicine Finland, FIMM, Helsinki Institute of Life Science
(HiLIFE), University of Helsinki, Biomedicum 2U, Tukholmankatu 8, 00290 Helsinki, Finland
| | - Salvatore Russo
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Antti Rannikko
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
- Department
of Urology, Helsinki University and Helsinki
University Hospital, Haartmaninkatu 8, 00029 Helsinki, Finland
- Research
Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, 00029 Helsinki, Finland
| | - Manlio Fusciello
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Satu Koskela
- Research
& Development Finnish Red Cross Blood Service Helsinki, Kivihaantie 7, 00310 Helsinki, Finland
| | - Jukka Partanen
- Research
& Development Finnish Red Cross Blood Service Helsinki, Kivihaantie 7, 00310 Helsinki, Finland
| | - Firas Hamdan
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Sari M. Tähkä
- Drug
Research Program, Division of Pharmaceutical Chemistry and Technology,
Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
| | - Erkko Ylösmäki
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Dario Greco
- Faculty
of
Medicine and Health Technology, Tampere
University, Arvo Ylpön
katu 34, Tampere 33520, Finland
| | - Mikaela Grönholm
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
| | - Tuija Kekarainen
- Kuopio
Center for Gene and Cell Therapy, Microkatu 1S, 70210 Kuopio, Finland
| | - Masoumeh Eshaghi
- Kuopio
Center for Gene and Cell Therapy, Microkatu 1S, 70210 Kuopio, Finland
| | - Olga L. Gurvich
- Kuopio
Center for Gene and Cell Therapy, Microkatu 1S, 70210 Kuopio, Finland
| | - Seppo Ylä-Herttuala
- A.
I. Virtanen Institute, University of Eastern
Finland, Neulaniementie
2, 70211 Kuopio, Finland
| | - Rui M. M. Branca
- Science
for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Tomtebodavagen 23B, 171 21 Solna, Sweden
| | - Janne Lehtiö
- Science
for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Tomtebodavagen 23B, 171 21 Solna, Sweden
| | - Tiina M. Sikanen
- Drug
Research Program, Division of Pharmaceutical Chemistry and Technology,
Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
| | - Vincenzo Cerullo
- Drug
Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical
Biosciences, Faculty of Pharmacy, University
of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
- Helsinki
Institute of Life Science (HiLIFE), University
of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland
- Translational
Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland
- Digital
Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland
- Department
of Molecular Medicine and Medical Biotechnology, Naples University “Federico II”, S. Pansini 5, 80131 Naples, Italy
| |
Collapse
|